Hester Biosciences Limited — Board Meeting, 28-10-2024: Outcome of Board Meeting

Hester Biosciences reported strong financial results for Q2 and H1 FY25, with standalone product sales rising 12% and profits increasing 38%. Consolidated results showed a 21% rise in product sales and a remarkable 108% jump in profit. Key drivers included growth in both the Poultry and Animal Healthcare divisions, alongside successful product launches and sales enhancements. The company's earnings per share for Q2 stood at ₹10.97, reflecting improved operational efficiency.